TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Authors

Yusuf Yilmaz, Gupse Adali, Ilkay Ergenc, Eda Kaya, Dilara Turan Gokce, Caglayan Keklikkiran, Mujdat Zeybel, Gediz Dogay Us, Bulent Degertekin, Ramazan Idilman, Turkish Association for the Study of the Liver (TASL) Obesity Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Special Interest Group (SIG), Ulus Salih Akarca, Zeki Karasu, Sabahattin Kaymakoglu, Nurdan Tozun, Ahmet Uygun

Published in

Hepatology forum. Volume 7. Issue 3. Pages 177-214. Epub Jul 27, 2026.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and represents a major and growing public health challenge in Türkiye. This guidance provides an updated, clinically oriented overview of the definition, epidemiology, screening, diagnosis, risk stratification, and management of MASLD, with particular emphasis on evolving nomenclature, non-invasive diagnostic pathways, and current treatment strategies. The document addresses the full clinical spectrum of disease, from steatosis and metabolic dysfunction-associated steatohepatitis (MASH) to advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplantation. The guidance also incorporates evidence and practice considerations relevant to the Turkish population, including local epidemiology, resource availability, and implementation challenges in real-world care. Finally, areas of uncertainty and evidence gaps are highlighted to support future research and locally relevant policy development.

PMID:
42609490
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.